GlobalData analysts anticipate FDA approval for the JenaValve Trilogy TAVR device designed to treat aortic regurgitation (AR) ...

SGMC Health recently achieved the successful completion of its first transcarotid access Transcatheter Aortic Valve ...

Medtronic plc MDT is likely to grow in the coming ... Within Structural Heart, MDT won TAVR (Transcatheter aortic valve replacement) share globally in the fiscal third quarter on the strength ...

system by 2028 Clinicians show a clear preference for BEV TAVR systems over self-expanding (SEV) systems from Medtronic plc. MDT and Abbott Laboratories ABT. The analyst points out that DurAVR ...

Importantly, the Medtronic CoreValve device ... STS: Society of Thoracic Surgeons; TAVI: Transcatheter aortic valve implantation. Transcatheter aortic valve implantation (TAVI) has demonstrated ...

Medtronic plc’s MDT strength in the Cardiovascular business is poised to drive growth in the upcoming quarters. The company’s Neuroscience portfolio's growth prospects look highly promising.

Risk for bleeding events is significantly affected by DOAC score in patients with atrial fibrillation who have received TAVR.

As the first Medtronic self-expanding TAVR system approved in China, the Evolut PRO system approval is based on clinical data from more than 32,000 patients, which showed high survival ...